Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546669 | 0.88 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL10260946 | 0.87 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL1109858 | 0.85 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL294988 | 0.83 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL12670076 | 0.81 | AAK1 (0.36) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL1712653 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL7905771 | 0.81 | CA14 (0.44) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL14157484 | 0.81 | CA14 (0.47) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL98924 | 0.81 | CHRNB2 (0.44) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL19699862 | 0.81 | CHRM2 (0.39) | HDAC6HDAC1HDAC2CA14PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111620870-B | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2023-01-03 | — | — | CN | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-111620870-A | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-106414445-B | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2020-07-03 | — | — | CN | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| CN-1538951-A | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells | ��ķ�ɷ�����˾ | 2004-10-20 | — | — | CN | disclosed |
| CN-1107151-A | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-08-23 | — | — | CN | disclosed |
| CN-1028527-C | Process for preparing coumarin derivatives | SANKYO CO (JP) | 1995-05-24 | — | — | CN | disclosed |
| CN-1026892-C | New amino acid derivatives, process for preparation thereof and pharmaceutical composition comprising same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-12-07 | — | — | CN | disclosed |
| CN-1074214-A | The preparation method of isoquinoline sulfone amide derivative | JOHNSON MATTHEY PLC (JP) | 1993-07-14 | — | — | CN | disclosed |
| CN-1049662-A | Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder | SANKYO CO (JP) | 1991-03-06 | — | — | CN | disclosed |
| CN-1044098-A | Compounds with vascular smooth muscle relaxing activity | HIDAKA HIROYOSHI (JP) | 1990-07-25 | — | — | CN | disclosed |
| CN-1030411-A | New amino acid derivatives, its preparation method and contain its pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC6 405/4885HDAC1 849/4885HDAC2 719/4885 |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC6 405/4885HDAC1 849/4885HDAC2 719/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | HDAC6 464/4885HDAC1 935/4885HDAC2 795/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC6 405/4885HDAC1 849/4885HDAC2 719/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC6 405/4885HDAC1 849/4885HDAC2 719/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | HDAC6 464/4885HDAC1 935/4885HDAC2 795/4885 |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC6 405/4885HDAC1 849/4885HDAC2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.